DNMT3B and neoplasm: Western blot analysis of tumor tissues showed that treatment with sorafenib plus CHIR-99021 not only sufficiently inhibited DNMT3B expression but also increased Cleaved-PARP expression relative to that observed with sorafenib treatment alone in vivo (Fig. 6E).